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Abstract  
Introduction: Drugs marketed during the last few years (i.e. Lacosamide, Ruifinamide, 
Eslicarbazepine acetate, Brivaracetam and Perampanel) are increasingly regarded as third 
generation AEDs. This paper presents available data about monotherapy with third generation drugs 
and on-going clinical trials with special attention to the existing debate about monotherapy license 
in epilepsy. 
Areas covered: References were identified by searches of Medline/PubMed. In addition, currently 
active studies for these AEDs were identified in the ClinicalTrials.gov database.    
Expert commentary: Results of studies on Eslicarbazepine acetate and Lacosamide clearly suggest 
good efficacy and tolerability. The selective pharmacological profile, the lack of interactions, the 
good tolerability with low propensity for cognitive side effects and the availability of different 
pharmacological formulations represent evident advantages. Although third generation 
monotherapies are quite promising, long-term safety data is needed in order to understand how 
these compounds will place in the current armamentarium.  
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1. INTRODUCTION 
Epilepsy is one of the most common and serious neurological conditions with incidence 
rates, in high-income countries, ranging between 40 and 70/100,000 persons/year, generally higher 
in young children and in elderly people, while in resource-poor countries the incidence is usually 
much higher, often above 120/100,000/year [1]. Antiepileptic drugs (AEDs) remain the mainstay of 
the epilepsy treatment and at least two thirds of people with epilepsy become seizure free on one or 
more drugs [2]. During the last two decades a new AED was launched almost annually potentially 
increasing the number of therapeutic options and making long-term safety a crucial point in epilepsy 
care. Drugs marketed during the last few years (i.e. Lacosamide, Ruifinamide, Eslicarbazepine 
acetate, Brivaracetam and Perampanel) are increasingly regarded as third generation drugs [3] 
because some of them (i.e. Eslicarbazepine and Brivaracetam) represent a third generation in drug 
improvement (Figure 1) and others (i.e. Rufinamide, Lacosamide and Perampanel) have new 
mechanisms of actions and clean pharmacological profile. In the North American literature, 
Clobazam and Vigabatrin are sometimes included in this list although this is probably inappropriate 
considering the extensive literature already published on these compounds.  
In 2006, the Subcommission on AEDs guidelines of the International League Against Epilepsy 
(ILAE) published a review [4], updated in 2013 [5], aimed at providing an evidence-based approach 
to initial monotherapy in patients with newly diagnosed or untreated epilepsy (Table 1). This 
document emphasised a few major points: (i) the alarming lack of well-designed, properly conducted 
randomised control trials (RCTs) for patients with generalized seizures/epilepsies and for children in 
general; (ii) the number of methodological problems for available randomised control trials (RCTs) 
that limit their applicability; (iii) that the ultimate choice of an AED for any individual patient with 
newly diagnosed or untreated epilepsy should include consideration of all possible variables (i.e. AED 
safety and tolerability, pharmacokinetic properties, formulations, and expense) and not just efficacy 
and effectiveness. Although the ILAE document was not intended to be used for regulatory 
purposes, it reiterated the importance of RCTs to guide treatment choices.  
Almost all AEDs obtain initial approval to be marketed through an "add-on" clinical trial design, 
which means adding the investigational medication or placebo to one or more baseline medications. 
After this step most of AEDs go through the monotherapy approval with additional studies. The 
majority of second generation compounds are now licensed for monotherapy, at least in the 
European Union (EU). It is, therefore, possible that most of third generation drugs will follow the 
same steps. The aim of the present paper is to review available data on marketed third generation 
AEDs currently under Phase III for monotherapy in adults with epilepsy and to discuss current 
issues in the regulatory process for monotherapy. References were identified by searches of 
Medline/PubMed until 30 January 2016 using the terms “monotherapy” and “Lacosamide”, 
“Rufinamide”, “Retigabine”, “Eslicarbazepine acetate”, “Brivaracetam” and “Perampanel”. In 
addition, currently active studies for these AEDs were identified in the ClinicalTrials.gov database.  
Only papers published in peer-reviewed journals were included. 
 
2. STUDIES ON INDIVIDUAL DRUGS 
There were no monotherapy studies (either published or on-going) for Rufinamide, Perampanel or 
Retigabine. Therefore, the paper focuses on Eslicarbazepine acetate (ESL), Lacosamide (LCM) and 
Brivaracetam (BRV). 
 
2.1 Eslicarbazepine acetate 
ESL is a third-generation member of a long-established family of AEDs, namely carbamazepine (CBZ) 
(first-generation) and oxcarbazepine (OXC) (second-generation) [6]. ESL is a pro-drug of 
eslicarbazepine, which is also the primary metabolite of OXC. It shares with CBZ and OXC the 
dibenzazepine nucleus bearing the 5-carboxamide substitute but it is structurally different at the 
10,11-position. This molecular variation results in differences in metabolism and seems to be 
responsible for improved tolerability and ease of administration (once daily dosing). In fact, unlike 
CBZ, ESL is not metabolized to 10,11-epoxide and is not susceptible to induction of its own 
metabolism [6]. Although the precise mechanism of the anticonvulsant activity of ESL is unknown, it 
is thought to involve inhibition of voltage-gated sodium channels [6]. ESL has a linear 
pharmacokinetics and, although it does not seem to be an inducer, the EU Summary of Product 
Characteristics (SPC) recommends closely monitoring of the International Normalised Ratio (INR) 
during the first weeks after starting or stopping warfarin when prescribed in combination with ESL 
[6]. 
The Food and Drug Administration (FDA) has recently approved ESL as monotherapy for 
adult patients with partial-onset seizures in the United States (US) but it is still not licensed in EU. 
The FDA approval was based on two Phase III conversion to monotherapy trials [7,8]. Both studies 
were 18-week, multicentre, randomized, double-blind trials of gradual conversion to ESL 
monotherapy in adults with partial-onset seizures not well controlled by 1–2 AEDs. The 
monotherapy period was 10 weeks in both studies. Historical controls were used in both studies. 
One study was mainly based in North America [8] while the other one had an equal distribution 
between US and non-US recruitment centres [7]. In the North American study, the reduction in 
median standardized seizure frequency (seizures per 28 days) between baseline and the 18-week 
treatment period was 31% for ESL 1200 mg and 42% for ESL 1600 mg [8]. In the other study, the 
responder rates (a 50% or greater reduction in seizure frequency from baseline) during the 18-week 
double-blind period and the monotherapy period, respectively, were 35.2% and 38.9% for ESL 1200 
mg, and 46.0% and 46.0% for ESL 1600 mg [7] (Table 2). A recently published pool analysis of these 
two studies provided Class IV evidence that for adults with medically uncontrolled partial-onset 
seizures, ESL monotherapy is well tolerated and effective [9]. 
In terms of safety, at least one treatment emergent adverse event (TEAE) was reported by 67% [7] 
and 89% [8] of patients in the two samples and in both studies mainly during the titration period 
with a prevalence of TEAEs in the monotherapy phase ranging between 38% and 49%. In the 
majority of cases, TEAEs were mild to moderate in severity and the commonest were dizziness, 
headache, fatigue, somnolence and nausea (Table 3). The discontinuation rate due to TEAEs was in 
the region of 7%. Changes in sodium levels were reported in around 7% of cases, no patients 
presented sodium levels below 125 mEq/l in the non-US study [7], while 4% reported in the North 
American study [8].  
Two Phase III studies of ESL are currently on-going (Table 4). BIA-2093-311 is a double-blind, 
randomized, active-controlled, parallel-group, multicentre study comparing ESL with Carbamazepine 
Controlled Release (CBZ-CR) according to the following scheme: week 1 and 2 either 400mg/day ESL 
or 200mg/day CBZ-CR; Week 3 onwards either 800mg/day ESL or 400mg/day CBZ-CR. The dose 
would be then maintained unless a subject has a seizure and in that case the assigned treatment 
dose would be increased to ESL 1200mg/day or CBZ-CR 800mg/day up to ESL 1600mg/day or CBZ 
1200mg/day. Subjects who remain seizure free for 26 weeks at any dose during the evaluation 
period will continue to receive the allocated treatment under double-blind conditions. The second 
Phase III trial is the open label extension phase of subjects who took part in the BIA-2093-311 trial in 
order to have further safety and efficacy data. These studies will allow monotherapy indication in 
the EU. 
 
2.2 Lacosamide 
LCM seems to have a novel mechanism of action, namely the enhancement of the slow inactivation 
of voltage-gated sodium channels and the modulation of the collapsing-response mediator protein 2 
(CRMP-2) which seems to regulate N-type voltage-gated calcium channels, although LCM does not 
appear to affect N- or P/Q-type calcium channels in animal studies (10). LCM has a linear 
pharmacokinetics and no significant interactions are reported although the EU SPC advices advises 
caution with the coadministration of LCM and strong CYP2C9 (e.g. fluconazole) and CYP3A4 (e.g. 
clarithromycin, ketoconazole, ritonavir) inhibitors [10]. 
The FDA has approved LCM for the monotherapy of partial-onset seizures in patients older 
than 17 years in the US but it is still not available for this indication in the EU. Three published 
studies were identified for LCM. A Phase III, double-blind, conversion to monotherapy trial [11] and 
two open, conversion to monotherapy trials, one with a prospective [12] and another one with a 
retrospective design [13]. 
The first study is a historical-controlled, double-blind study of patients aged 16–70 years on stable 
doses of 1–2 AEDs and experiencing 2–40 partial-onset seizures per 28 days during the 8-week 
prospective baseline period. Patients were then randomized to LCM 400 or 300 mg/day (3:1 ratio), 
starting at 200 mg/day and titrated over 3 weeks to randomized dose. Background AEDs were then 
withdrawn over 6 weeks and patients entered a 10-week monotherapy phase. In the 400 mg/day 
group, 41.7% had a ≥50% reduction in seizure frequency during the 10-week monotherapy phase 
compared with baseline; 24.1% ≥75% reduction in seizure frequency and 14.9% remained seizure-
free. The proportion of patients in the 300 mg/day group with ≥50% or ≥75% reduction in seizure 
frequency or who became seizure-free was comparable to that seen in the 400 mg/day group [11]. 
An open, single centre study in 58 patients showed that 63.8% retained LCM at 1 year from 
withdrawal of background AED and 32 (55.2%) remained seizure free [12]. A retrospective audit of 
66 patients collected in six centres in Spain showed that two thirds of patients remained seizure free 
on LCM monotherapy [13] but these results are obviously of little value as this report is limited by a 
number of important methodological limitations such as the retrospective design and the 
heterogeneity of epileptic syndromes and clinical scenarios.   
In terms of safety, at least 84.5% reported at least one TEAE that was mild to moderate in severity 
and mainly during the titration period. The commonest TEAEs were dizziness, headache and nausea. 
Discontinuation rate due to TEAEs was in the region of 15% [11] (Table 3).  
In terms of on-going trials, SP0993 is already completed but results are not yet available. This is a 
multicentre, double-blind, double-dummy, randomized, active-controlled study comparing LCM (200 
to 600 mg) to CBZ-CR (400 to 1200 mg). Patients recruited in this study will enter in SP0994 that is a 
multicentre, double-blind, follow up study evaluating the long-term safety of LCM in comparison 
with CBZ-CR with an observation phase of maximum 3.5 years. SP0994 will have an open-label, 
flexible-dose, extension-phase in order to collect additional monotherapy safety data. Finally, a 
multicentre, open-label, long-term study is investigating safety of conversion to LCM monotherapy 
at doses up to 600 mg in Japanese adults with partial-onset seizures.  
 
2.3 Brivaracetam 
BRV is the evolution of a family of AEDs, namely levetiracetam (LEV) and piracetam. It has a 10-fold 
higher affinity for the SV2A protein than LEV and, in contrast to LEV, also displays inhibitory activity 
on voltage-gated sodium channels [14]. BRV has a linear pharmacokinetics and no relevant 
interactions are reported [14]. 
No published studies are currently available. Two Phase III studies have just terminated 
NO1276 and NO1306. Both of them are double-blind, randomized, multicentre, parallel group, 
historical-control conversion to monotherapy studies in patients with partial-onset seizures (Table 
4). In both cases, patients are randomised to either BRV 50 mg or 100 mg for a 17-week evaluation 
period. These studies have been designed to have a monotherapy license in the US. 
 
3. DISCUSSION 
Despite the large amount of data on drug refractory epileptic syndromes, studies on 
treatment of newly diagnosed patients with epilepsy are still limited. In fact, even large cohort 
studies often present data on mix of newly diagnosed and chronic patients that are obviously 
representative of the general population but bring limited information on outcomes of newly 
diagnosed patients. The SANAD trial represented a first attempt to identify pragmatic algorithms of 
treatment in newly diagnosed patients [15] but it was heavily criticised in terms of methodology and 
significance of their results [16–18].  
There is general agreement that up to 49% of newly diagnosed patients with epilepsy become 
seizure free on their first AED and an additional 30% on a second regimen as either monotherapy or 
in combination with another agent [19,20]. In addition, in 60% of patients, it is possible to identify a 
constant course as either becoming/remaining seizure free shortly after commencing treatment or 
having persistent seizures despite different AED trials [20]. This data has to be considered when 
discussing efficacy of monotherapies with third generation AEDs as it is evident that newly 
diagnosed patients are more likely to respond to any treatment and what probably makes the 
difference is long term safety. In this regard, ESL, LCM and BRV have the advantage of a clean 
pharmacokinetics with a lack of interaction [3]. In addition, preliminary studies suggest a 
favourable tolerability profile with no deleterious effects on cognitive functions [21]. Further 
safety data is needed especially on weight gain, bone health and malformation rates during 
pregnancy as these variables will make the difference in terms of future success of third generation 
AEDs as initial monotherapies. In fact, it is now established that, although seizure freedom is an 
important predictor for quality of life in people with epilepsy, other factors such as mood and the 
adverse effects of medications are far stronger predictors [22]. In fact, although current results 
suggest that both LCM and ESL can be considered valuable options in newly diagnosed patients and 
BRV will probably produce positive results as well, how these compounds will place in the current 
armamentarium of treatment is far from being elucidated without long-term safety data.  
 
The regulatory process for monotherapy license of AEDs is currently the main focus of 
discussion. In fact, while first generation drugs were not subjected to the regulatory standards of the 
FDA or the European Medicines Agency (EMA), second- and third-generation compounds have been 
evaluated in rigorous randomised controlled trials. As already stated, AEDs usually obtain a first 
regulatory approval as “add-on” but efficacy information obtained from this type of studies is not 
considered sufficient for monotherapy approval mainly because safety data are biased by possible 
interactions with concomitant medications. However, the FDA and the EMA have different views for 
monotherapy approval. In fact, while the FDA requires demonstration of a difference in treatment 
effect between the study drug and placebo or active comparator, the EMA requires therapeutic non-
inferiority, or equivalence, between the study drug and a standard therapy. These differences have a 
number of relevant repercussions as they impose expensive obligations on pharmaceutical 
companies developing new AEDs in order to get a licence for monotherapy, leading to reduced 
investments in epilepsy research and, most importantly, a paucity of monotherapy options for 
patients with epilepsy. Paradoxically, while a patient with partial onset seizures who doesn’t respond 
to a first AED can choose among 20 different drugs, a newly diagnosed untreated patient can choose 
only among a few options and this is against any tailored-treatment approach.  
Both the FDA and the EMA approaches have limitations. In fact, in the FDA’s view, newly diagnosed 
patients should be randomly assigned to the study drug or to the placebo but this is considered 
unethical. For this reason, studies for FDA approval have a withdrawal to monotherapy design where 
treatment resistant patients are converted from their existing drug to the study drug in 
monotherapy and their outcome compared with a virtual control group modelled from a meta-
analysis of previous conversion to monotherapy studies. The unblind design is the first evident 
limitation but it is also important to emphasise that the comparison with historical studies 
completed decades ago represents another major concern as there is clear evidence for population 
and placebo rate changes over time [23]. Conversely, the ideal study for the EMA is a long-term, 
non-inferiority active control trial to a standard AED. Although this approach has a number of 
advantages (i.e. specific and meaningful endpoints, active comparator, individualized treatment), it 
is evident that this design per se cannot distinguish between effective and ineffective treatments 
and cannot exclude that a placebo would have behaved similarly. In fact, according to this approach, 
two equally weakly effective or ineffective treatments would perform similarly and this is even more 
relevant in monotherapy studies as up to 50% of newly diagnosed patients become seizure free on 
their first treatment.  
Although there is general agreement that different licensing mechanisms for adjunctive treatment 
and monotherapy are not supported by any clinical and scientific rational, it must be acknowledged 
that without monotherapy trials, clinicians may use new drugs in newly diagnosed patients without 
enough time to identify serious adverse events that are usually identified after a large number of 
patients are exposed. This specific issue could be potentially overcome encouraging post-
authorisation Phase IV studies in a sequential licensing process and the advantages of this process 
have been clearly identified [23,24]. It is evident that a unified protocol for monotherapy indication 
of AEDs is urgently needed as well as properly-designed studies to implement evidence-based 
guidelines of treatment of newly diagnosed patients with epilepsy. 
 
4. CONCLUSIONS  
Current studies suggest that ESL, LCM and possibly BRV, will be valuable options for the initial 
monotherapy of patients with localization-related epilepsies. The low impact on cognitive functions, 
the lack of pharmacokinetic interactions and the selective pharmacological profile represent 
important advantages. Long-term safety data from Phase IV studies are needed especially regarding, 
weight gain, bone-health and malformation rates. New policies for monotherapy license for AEDs 
are needed in order to promote further research into epilepsy treatments. 
  
5. EXPERT COMMENTARY 
Results of studies on ESL and LCM clearly suggest good efficacy and tolerability. The selective 
pharmacological profile, the lack of interactions and the good tolerability with low propensity for 
cognitive side effects represent evident advantages. In addition, in the case of LCM, different 
formulations are available (i.e. tablets, liquid oral solution and liquid intravenous solution), offering a 
wide range of applications in different clinical scenarios. It is quite likely that BRV will be as 
successful as ESL and LCM in the withdrawal to monotherapy studies and will be licensed for 
monotherapy in the US but studies are still on going. In this regard, it is becoming evident that new 
policies for the monotherapy indication of AEDs are urgently needed in order to offer as many 
options as possible to patients with newly diagnosed epilepsies. This is particularly important for 
generalised epilepsy syndromes where the number of licensed drugs is quite limited and some drugs 
are burdened by unacceptable side effects (i.e. valproate in women of child bearing age). It has to be 
admitted that pharmaceutical companies are progressively leaving the epilepsy field because of 
these somehow byzantine regulatory protocols and this is not acceptable for the many patients 
developing epilepsy every year that are entitle to have better and better options in terms of efficacy, 
tolerability, long-term safety and easy ways of administration. The proposal of a sequential licensing 
process based on Phase IV studies represents an interesting option to have clear safety data and to 
simplify the license process at the same time. 
 
6. FIVE YEARS VIEW 
Third generation AEDs showed clear advantages in terms of selective mechanisms of action, lack of 
side effects on cognitive functions and lack of interactions. Most of them are already licensed for 
monotherapy in US (i.e. ESL and LCM) and they will be probably available in Europe for monotherapy 
as well. Current data suggests that these AEDs have a low propensity for side effects and are 
generally well tolerated. The titration regime is quite simple for all of them and this represents 
another important advantage. Previous AEDs, such as LEV, that showed a similar balance between 
efficacy and safety, became rapidly popular in the epilepsy treatment. For this reason, it is possible 
to hypothesize that they will also become increasingly popular and widely prescribed if major safety 
issues do not come up. LCM and BRV are also available for the intravenous administration being an 
important option in the acute setting. While in the EU there are a number of AEDs already licensed 
for monotherapy, in the US mainly first generation AEDs are available. Therefore, it is possible to 
hypothesis that they will become extremely popular in the US market. As long-term safety 
represents an important variable for monotherapies in epilepsy, data from pregnancy registers and 
Phase IV studies will clearly decide on the success of third generation AEDs for newly diagnosed 
patients. 
 
7. KEY ISSUE 
 
 Lack of significant drug-drug interactions, life-threatening adverse events and negative impact 
on cognition are significant advantages of third generation antiepileptic drugs   
 Data on monotherapy are available for LCM and ESL while for BRV trials are currently on going 
 LCM and ESL are already licensed for monotherapy in US 
 Available studies suggest good efficacy and tolerability for LCM and ESL but long term safety 
data is needed especially regarding teratogenicity, bone health and weight gain  
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FIGURE LEGEND 
Figure 1. Examples of the three generations antiepileptic drugs. 
